Endo Health Solutions Reports Above Expectations $785M Revenue Increase

Endo Health Solutions’ quarterly profit of anesthetic and generic drugs beat analysts’ expectations with a $785 million — or 29 percent — revenue increase, according to Reuters.

Advertisement

Generic drug sales increased 20 percent and sales of the anesthetic Lidoderm increased 16 percent. Stocks ended at $1.27 per share, above expectations of $1.18 per share.

Lower expectations were due in part to two patent lawsuit settlements.

More Articles on Anesthesia:
First Grad Completes TeamHealth Anesthesia Management Fellowship
Colorado Court Says CRNAs Can Administer Anesthesia
Somnia Releases White Paper on Anesthesia’s Role in Perioperative Management

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.